ACTRN12610000590066
10 evidence topics · 1 source
Objective
Location and study date
Study design
Eligibility criteria
Quitline population
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome
| Characteristic | Quoted value |
|---|---|
| Ascertainment | “self-reported” |
| Continuous-abstinence assessment | “1 month” |
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
| Characteristic | Quoted value |
|---|---|
| Total randomized | “1310” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
Treatment was open-label and the primary outcome was self-reported abstinence at one month. Cytisine and nicotine replacement therapy were given for different durations. These features limit blinding and comparability with trials using biochemical verification as the primary outcome.